Neumora receives Nasdaq bid price notice; has until April 26, 2027 to regain compliance
Neumora Therapeutics received a Nasdaq notice on October 26, 2026 that its common stock is below the $1.00 minimum bid price required for continued listing on the Nasdaq Global Select Market. The company has 180 calendar days, until April 26, 2027, to regain compliance, and the filing states there can be no assurance it will do so, which raises the risk of future delisting for shareholders.
Key points
- Nasdaq notice received October 26, 2026 under Listing Rule 5450(a)(1) for the $1.00 minimum bid price
- Compliance period runs 180 calendar days, until April 26, 2027
- Regaining compliance requires a closing bid of at least $1.00 per share for ten consecutive business days
- If not compliant, the company may need to apply to transfer to The Nasdaq Capital Market and may consider a reverse stock split
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.